CS Paper Radar

Toward a Locally Deployable Agentic Co-Scientist: Small-Model Planning for Early-Stage Drug Discovery

Tian Liang, Jiayu Chang, Alejandro F. Frangi, Mobarak I. Hoque, Richard A. Bryce

cs.AI ·submitted 2026-10-03 20:09 UTC · v1
published

Abstract

Early-stage computational drug discovery requires coordinating heterogeneous scientific tools across multi-step workflows. We present a lightweight, tool-augmented framework in which a locally deployable compact language model plans calls to 18 modular tools. A Unified Molecular Schema maintains shared molecular records, while a plug-in interface supports tool replacement and extension. We construct 1,263 manually refined query-plan pairs through workflow-graph path coverage and apply LoRA fine-tuning to three compact model families. Under the query-level split, all fine-tuned models generate fully parseable and schema-compliant plans on 47 held-out cross-group queries. Llama 3.2-3B achieves a tool-selection F1 of 0.998, sequence exact match of 0.979, and argument F1 of 0.960. Under the stricter workflow-grouped split, which excludes identical ordered tool sequences across partitions, sequence exact match reaches 0.452 to 0.548, highlighting the remaining difficulty for compact models in generating complete workflow paths unseen during training. These results demonstrate the feasibility of compact, locally deployable planning while identifying compositional generalization as an important direction for further improvement.

Comment
22 pages, 4 figures. Accepted at the AI for Drug Discovery Workshop, NeurIPS 2026

Closest papers

Nearest neighbours by meaning across the whole index.

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

cs.AI cs.MAq-bio.BM ·2026-11-02 ·Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang +11 more
benchmark similarity 0.76
Abstract · 63 pages, 13 figures, including Supporting Information

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

0.08

DrugCoding: A Scientific Programming Agent for Drug Discovery

cs.AI cs.MA ·2026-11-10 ·Junwei Hu, Zhuohao Lin, Kun Li, Hengnan Zhang
benchmark similarity 0.75
Abstract

Drug discovery involves multiple interconnected research stages, including molecular design, property prediction, and virtual screening. These processes are characterized by complex workflows, interdependent computational tasks, and diverse specialized tools, placing substantial demands on the coordination of scientific models and computational resources. However, existing large language model (LLM)-based scientific agents still face challenges in autonomous planning of complex tasks, adaptive selection of specialized models, and reliable execution of multi-stage scientific computations, limiting their effectiveness in automating complex drug discovery workflows. To address these challenges, we propose DrugCoding, a scientific programming agent system that integrates scientific task planning, adaptive model routing, multi-agent collaboration, and programmatic tool execution. DrugCoding enables autonomous task planning and dynamic model adaptation for complex research objectives. It can flexibly invoke specialized scientific models, autonomously generate and execute code according to task requirements, and leverage multi-agent collaboration to support efficient execution and reliable validation of complex scientific tasks. To evaluate DrugCoding's performance in scientific tool invocation and multi-stage task execution, we conduct multi-turn tool-calling experiments across diverse language models and scientific tool interfaces. Experimental results demonstrate that DrugCoding achieves an average session-level Pass@1 of 97.35% on the full benchmark, outperforming the strongest baseline, Codex, by 9.24%. On the challenging subset, DrugCoding achieves 97.92%, exceeding the strongest baseline.

0.18

MADDIE: Multi-Agent Drug Discovery Engine

cs.AI ·2026-10-12 ·Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao +2 more
code/data similarity 0.74
Abstract

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.

0.29

M3OS: A Monte Carlo Graph Search-Orchestrated Multi-Agent LLM System for Evidence-Traced Molecular Optimization

cs.LG q-bio.BM ·2026-09-28 ·Junjie Wang, Yaowei Jin, Ruohui Tang, Guonan Cui, Haojie Wang +5 more
similarity 0.69
Abstract

Small-molecule optimization integrates medicinal-chemistry reasoning and computational evidence through iterative, multi-objective decisions. When large language models (LLMs) reason over optimization histories stored primarily in conversational context, they must recover candidate identities, prior evaluations, and task constraints to guide subsequent decisions. We present M3OS, a multi-agent LLM system that decouples molecular-design reasoning from optimization-state management through Monte Carlo graph search. A persistent graph links evaluated candidates, parent-child transformations and evaluation evidence, while rewards and visit statistics guide LLM-assisted parent selection. Two branches combine tool-driven candidate generation with knowledge- and case-guided medicinal-chemistry editing. An execution harness controls graph updates through structured output extraction, molecular validation and task-bound evaluation. Agents receive role-specific contexts, while the graph preserves optimization trajectories beyond their active contexts. Across three molecular optimization benchmarks, M3OS achieves higher success rates than baselines, supporting the integration of persistent search state, specialized agents and controlled execution for multi-constraint optimization.

0.21

MolDesignBench: Evaluating LLM-based Agent for Scenario-grounded Molecular Design

cs.AI cs.LG ·2026-09-23 ·Yongjun Jeong, Hanbum Ko, Ye Rin Kim, Chanhui Lee, Rodrigo Hormazabal +4 more
publishedbenchmarkcode/data similarity 0.67
Abstract · Accepted to COLM 2026

Real-world molecular design remains challenging for large language model (LLM)-based agents. It requires them to interpret design contexts, satisfy multiple constraints, identify infeasible specifications, and reason over multi-step tool outputs. Existing benchmarks do not capture this complexity, focusing instead on explicit and narrow constraints, only feasible problems, and single-path solutions. To address this gap, we propose MolDesignBench, a scenario-grounded benchmark that more closely reflects real-world molecular design for evaluating tool-augmented LLM agents. MolDesignBench comprises 2K generation and optimization instances that combine implicit requirements embedded in design narratives with explicit property and functional-group constraints, including infeasible cases, and require the effective use of 17 specialized chemistry tools. Experiments across diverse frontier LLMs reveal low success rates--with the best achieving only $\sim43$\%--and frequent failures in implicit-constraint reasoning, infeasibility detection, and tool reasoning. The corresponding fine-grained failure-mode analysis identifies implicit constraint interpretation and infeasibility detection as the primary bottlenecks, establishing MolDesignBench as a rigorous testbed to guide future research on chemical agents. The benchmark, tool interface, and evaluation code are publicly available.

0.28

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

cs.AI ·2026-10-29 ·Yikun Zhang, Xiwei Cheng, Mingze Yuan, Yu Zhang, Brian Shim +13 more
community pick similarity 0.67
Abstract · v2: updated the author list

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here we introduce MoLRSI, an AI agent that combines systematic optimization of workflows and model architectures with persistent cross-task memory to recursively improve its search policy for molecular discovery. Workflow performance, refinement outcomes, and execution feedback guide subsequent searches, allowing the agent to improve both its workflows and its strategy for developing them. We evaluate MoLRSI in two challenging molecular discovery settings that require balancing competing properties. In antibiotic discovery, MoLRSI developed a screening workflow balancing antibacterial activity, cytotoxicity and structural novelty, achieving an experimental hit rate of 15.9%, compared with 8.7% for a previous expert-led workflow using the same training data and screening library. In de novo peptide-MHC binder design, MoLRSI developed workflows that jointly consider target binding and specificity, producing eight experimentally validated hits against MART-1 and SARS-CoV-1 pMHCs with preferential binding over tested off-targets while Claude Science completely failed. These findings demonstrate how experience-guided workflow optimization can address competing discovery objectives while improving the search strategies used in subsequent campaigns.

0.39

Towards Agentic Scientific Discovery in Distributed Systems

cs.AI ·2026-11-15 ·Rashmita Soni, Abhirup Ghosh, Soumya Banerjee
similarity 0.66
Abstract

We investigate when adaptive tool selection helps identify a shared equation across clients with different input coverage. Query-ATLAS (query-conditioned Agentic Tool-based Learning for Aggregating Symbolic Equations) uses an LLM to guide symbolic search from client errors and previous proposals in a simulated distributed system. A four-architecture comparison reveals task-dependent opportunities: relative to fixed PySR-LLM, validation acceptances rise from 3/12 to 7/12 on CRK3 and from 11/12 to 12/12 on oscillator2, while MatSci3 favors the fixed workflow. Across 72 settings in a post-hoc six-task subset of eight development tasks, Query-ATLAS achieves 64 validation and 64 in-distribution passes, versus 62 and 59 for the fixed workflow; both pass 47/60 eligible out-of-distribution tests. The fixed workflow retains lower median errors and cost. Broader query coverage emerges as a promising benefit, motivating task-aware tool selection and client-aware fitting for scientific agents.

0.19

A local orchestration harness for molecular design with foundation models

cs.LG physics.chem-ph ·2026-10-20 ·Sakib Mostafa, Md Atik Ahamed, James Zou, Lei Xing, Md Tauhidul Islam
similarity 0.66
Abstract

Molecular design requires coordinated generation, property prediction and iterative editing, with each decision linked to the correct chemical structure and supporting evidence. Integrating these capabilities in practice presents three major challenges: retaining local control of molecular data, connecting specialized models across tasks and verifying that proposed changes satisfy chemical constraints. Here we present MolCrew, a locally deployable system that coordinates four separately trained molecular specialists with a language-model orchestrator and RDKit calculations. The specialists generate structures from descriptions, describe molecular structures, predict biological endpoints and propose edits towards specified goals. Separate model weights allow each capability to be evaluated and updated independently within the workflow. RDKit calculations check structural validity, quantify descriptor changes and assess specified structural constraints, while returned observations guide further tool calls. We evaluated low-rank adaptation of the orchestrator for tool-use decisions and failure recovery while leaving specialist weights unchanged. On 3,300 ChEBI-20 test examples, MolCrew achieved 96.4% exact structure recovery, compared with 38.7% for published Atomas-large results. Across eight MoleculeNet datasets evaluated using scaffold splits, mean area under the receiver operating characteristic curve was 0.851, compared with 0.770 for published Atomas results. In a recorded evaluation using the unadapted orchestrator, 1,554 of 1,699 requests (91.5%) passed every predefined workflow check. By preserving inspectable links between molecular proposals, model outputs and chemical calculations, MolCrew provides a modular framework for computational candidate assessment and refinement under local data control.

0.20